Stability Of Refractive Outcomes After Hyperopic Lasik With And Without Mitomycin C Application

The purpose of the study was to assess the efficacy and safety of hyperopic Laser-Assisted in Situ Keratomileusis (LASIK) with and without Mitomycin C (MMC) application, and to evaluate the stability of refractive outcomes.

This study was a prospective comparative randomized multicentral study conducted at five private practices in Bavaria (Augenlaserzentrum Frings®, Germany). Our study received approval from the local ethics committee and was registered at the German Clinical Trials Register. All patients gave informed consent for the use of their routinely collected data for research purposes.

This study included 140 hyperopic eyes, randomly assigned into two groups (A and B). Group A underwent hyperopic LASIK with MMC application, and Group B underwent conventional hyperopic LASIK without MMC use. The outcomes were evaluated using standard graphs for reporting refractive outcomes. Statistical analysis was performed using t-tests, Mann-Whitney tests, and Fisher's Exact Test, to assess differences in preoperative and postoperative parameters. The level of statistical significance was set at p < 0.05.

Both treatment groups showed highly effective and safe refractive outcomes, with no significant differences in postoperative uncorrected distance visual acuity (UDVA), corrected distance visual acuity (CDVA), or safety between the groups. No intraoperative complications or postoperative adverse events were observed. Age did not significantly affect the refractive outcomes and preoperative SE was not a significant predictor of refractive result.

Our study found no significant differences in refractive outcome parameters between hyperopic LASIK surgery with MMC and without MMC. These findings suggest that hyperopic LASIK with MMC is a safe and effective treatment option for hyperopia across different age groups and refractive errors. Longer follow-up periods and larger cohorts are needed to confirm these results.